Glucagon I pp 223-244 | Cite as

Heterogeneity of Circulating Glucagon and Glucagon-Like Immunoreactivity

  • I. Valverde
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 66 / 1)

Abstract

Multiple molecular forms of immunoreactive glucagon and glucagon-like immunoreactants have been described in various tissues and in the circulation. Some of these forms, as in the case of many other polypeptide hormones, may be related to glucagon biosynthesis (see Chaps. 6 and 7). At present, it is not clearly established whether the glucagon heterogeneity found in plasma is merely a reflection of that found in pancreatic or extrapancreatic tissues. The heterogeneity of circulating glucagon has been demonstrated by means of plasma gel filtration and subsequent glucagon radioimmunoassay of the eluates with different antisera.

Keywords

Obesity Filtration Polypeptide Arginine Trypsin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Assan R, Slusher N (1972) Structure/function and structure/immunoreactivity relationships of the glucagon molecule and related synthetic peptides. Diabetes 21: 843–855PubMedGoogle Scholar
  2. Bhathena SJ, Smith SS, Voyles NR, Penhos JC, Recant L (1977) Studies on submaxillary gland immunoreactive glucagon. Biochem Biophys Res Commun 74: 1574–1581PubMedCrossRefGoogle Scholar
  3. Boden G, Owen OE (1977) Familial hyperglucagonemia-An autosomal dominant disorder. N Engl J Med 296: 534–538PubMedCrossRefGoogle Scholar
  4. Boden G, Master RW, Rezvani I, Palmer JP, Lobe TE, Owen OE (1980) Glucagon deficiency and hyperaminoacidemia after total pancreatectomy. J Clin Invest 65: 706–716PubMedCrossRefGoogle Scholar
  5. Botha JL, Vinik AI, Child PT, Paul M, Jackson WPU (1977) Pancreatic glucagon-like immunoreactivity in a pancreatectomized patient. Horm Metab Res 9: 199–205PubMedCrossRefGoogle Scholar
  6. Chisholm DJ, Alford FP, Harewood MS, Findlay DM, Gray BN (1978) Nature and biologic activity of “extrapancreatic glucagon”: studies in pancreatectomized cats. Metabolism 27: 261–273PubMedCrossRefGoogle Scholar
  7. Conlon JM, Ipp E, Unger RH (1978) The molecular forms of immunoreactive glucagon secreted by the isolated, perfused dog pancreas. Life Sci 23: 1655–1658PubMedCrossRefGoogle Scholar
  8. Conlon JM, Rouiller D, Unger RH (1980) Characterization of the glucagon-like polypeptides released by the dog gut into the circulation. Biochem Soc Trans 8: 51–52PubMedGoogle Scholar
  9. Eisentraut A, Ohneda A, Parada E, Unger RH (1968) Immunologic discrimination between pancreatic glucagon and enteric glucagon-like immunoreactivity ( GLI) in tissues and plasma. Diabetes 17: 321Google Scholar
  10. Emmanouel DS, Jaspan JB, Kuku SF, Rubenstein AH, Katz Al (1976) Pathogenesis and characterization of hyperglucagonemia in the uremic rat. J Clin Invest 58: 1266–1272PubMedCrossRefGoogle Scholar
  11. Emmanouel DS, Jaspan JB, Rubenstein AH, Huen H-J, Fink E, Katz AI (1978) Glucagon metabolism in the rat. Contribution of the kidney to the metabolic clearance rate of the hormone. J Clin Invest 61: 6–13CrossRefGoogle Scholar
  12. Flanagan RWJ, Trimble ER, Conlon JM, Murphy RF (1975) Purification and characterization of plasma glucagon-like immunoreactivity by immunoaffinity chromatography. Diabetologia 11: 342Google Scholar
  13. Heding LG (1969) The production of glucagon antibodies in rabbits. Horm Metab 1: 87–88CrossRefGoogle Scholar
  14. Heding LG, Frandsen EK, Jacobsen H (1976) Structure-function relationship: immunologic. Metabolism [Suppl 1] 25: 1327–1329Google Scholar
  15. Hoist J J (1977) Extraction, gel filtration pattern, and receptor binding of porcine gastrointestinal glucagon-like immunoreactivity. Diabetologia 13: 159–169CrossRefGoogle Scholar
  16. Hoist JJ, Kreutzfeldt M, Holm G, Jensen E, Poulsen JSD, Sparso B, Sparso B, Schmidt A (1978) Absence of true pancreatic glucagon but persistence of circulating pancreatic glucagon-like immunoreactivity after pancreatectomy in pigs. Diab Metab 4: 74–79Google Scholar
  17. Hoist J J, Von Schenck H, Lindkaer S (1979) Gel filtration pattern of immunoreactive glucagon secreted by the isolated, perfused, porcine pancreas. Scand J Clin Lab Invest 39: 47–52CrossRefGoogle Scholar
  18. Iwasa S, Kondo K, Ueno H, Wakimasu M, Ohneda A (1981) Enzyme immunoassay for determination of pancreatic glucagon in plasma. Horm Metab Res 13: 14–17CrossRefGoogle Scholar
  19. Jaspan JB, Rubenstein AH (1977) Circulating glucagon. Plasma profiles and metabolism in health and disease. Diabetes 26: 887–902PubMedGoogle Scholar
  20. Jaspan JB, Huen AH-J, Morley CG, Moossa AR, Rubenstein AH (1977) The role of the liver in glucagon metabolism. J Clin Invest 60: 421–428PubMedCrossRefGoogle Scholar
  21. Jaspan JB, Polonsky KS, Lewis M, Pensler J, Pugh W, Moossa AR, Rubenstein AH (1981) Hepatic metabolism of glucagon in the dog. Contribution of liver to the overall metabolic disposal of glucagon. Am J Physiol 240: E233 - E244PubMedGoogle Scholar
  22. Krause U, Thiel M, Beyer J, Mangold G, Cordes U (1980) Glucagon secretion in four duo- denopancreatectomized patients after arginine and glucose load. Horm Metab Res 12: 364–369PubMedCrossRefGoogle Scholar
  23. Lawrence AM, Tan S, Hojvat TS, Kirsteins L (1977) Salivary gland hyperglycemic factor. An extrapancreatic source of glucagon-like material. Science 195: 70–72PubMedCrossRefGoogle Scholar
  24. Leclercq-Meyer V, Marchand J, Leclercq R (1980) Studies on the molecular forms of glu-cagon immunoreactivity ( GLI) released by the in vitro perfused rat pancreas. Dia-betologia 19: 294Google Scholar
  25. Mashiter K, Harding PE, Chou M, Mashiter GD, Stout J, Diamond D, Field JB (1975) Per-sistent pancreatic glucagon but not insulin response to arginine in pancreatectomized dogs. Endocrinology 96: 678–693PubMedCrossRefGoogle Scholar
  26. Matesanz R, Casado S, Valverde I, Hernando L (1977) Hyperglucagonemia and renal failure. Kidney Int 12: 84–85Google Scholar
  27. McDonald TJ, Dupre J, Caussignac Y, Radziuk J, Vliet SV (1979) Hyperglucagonemia in liver cirrhosis with portal-systemic venous anastomoses: responses of plasma glucagon and gastric inhibitory polypeptide to oral or intravenous glucose in cirrhotics with normal or elevated fasting plasma glucose levels. Metabolism 28: 300–307PubMedCrossRefGoogle Scholar
  28. Moody AJ, Jacobsen H, Sundby F, Frandsen EK, Baetens D, Orci L (1977) Heterogeneity of gut glucagon-like immunoreactivity (GLI). In: Foa PP, Bajaj JS, Foa NL (eds) Glucagon: its role in physiology and clinical medicine. Springer, Berlin Heidelberg New York, pp 129–136CrossRefGoogle Scholar
  29. Miiller WA, Berger M, Suter P, Cuppers HJ, Reiter J, Wyss T, Berchtold P, Schmidt FH, Assal J-P, Renold AE (1979) Glucagon immunoreactivities and amino acid profile in plasma of duodenopancreatectomized patients. J Clin Invest 63: 820–827CrossRefGoogle Scholar
  30. Munoz-Barragan L, Rufener C, Srikant CB, Dobbs RE, Shannon WA Jr, Baetens D, Unger RH (1977) Immunocytochemical evidence for glucagon-containing cells in the human stomach. Horm Metab Res 9: 37–39PubMedCrossRefGoogle Scholar
  31. O’Connor FA, Conlon JM, Buchanan KD, Murphy RF (1979) The use of perfused rat intestine to characterise the glucagon-like immunoreactivity released in serosal secretions following stimulation by glucose. Horm Metab Res 11: 19–23PubMedCrossRefGoogle Scholar
  32. Ohneda A, Horigome K, Yanbe A, Ishii S, Itabashi H, Chiba M, Maruhama Y, Yamagata S (1975) Plasma glucagon-like immunoreactivity ( GLI) in dogs. Tohoku J Exp Med 115: 337–343CrossRefGoogle Scholar
  33. Palmer JP, Werner PL, Benson JW, Ensinck JW (1978) Dominant inheritance of large mo-lecular weight immunoreactive glucagon. J Clin Invest 61: 763–769PubMedCrossRefGoogle Scholar
  34. Perez-Castillo A, Blazquez E (1980) Tissue distribution of glucagon, glucagon-like immunoreactivity, and insulin in the rat. Am J Physiol 238: E258 - E266PubMedGoogle Scholar
  35. Recant L, Perrino PV, Bhathena SJ, Danforth DN, Lavine RL (1976) Plasma immunoreactive glucagon fractions in four cases of glucagonoma. Increased “large glucagon-immunoreactivity. ” Diabetologia 12: 319–326PubMedCrossRefGoogle Scholar
  36. Rigopoulou D, Valverde I, Marco J, Faloona G, Unger RH (1970) Large glucagon immunoreactivity in extracts of pancreas. J Biol Chem 245: 496–501PubMedGoogle Scholar
  37. Rovira A, Lopez-Novoa JM, Ghiglione M, Zubiaur M, Pascual JM, Valverde I (1980) Lack of gut-GLI removal by the kidney. Diabetologia 19: 311Google Scholar
  38. Schwartz SS, Rich BH, Lucky AW, Strauss FH, Gonen B, Wolfsdorf J, Thorp FW, Burrington JD, Madden JD, Rubenstein AH, Rosenfield RL (1979) Familial nesidioblastosis: severe neonatal hypoglycemia in two families. Pediatrics 95: 44–53CrossRefGoogle Scholar
  39. Smith SS, Bhathena SJ, Nompleggi D, Penhos JC, Recant L (1978) Studies on persistent circulating immunoreactive glucagon (IRG) and immunoreactive insulin ( IRI) found in eviscerated rats with a functional liver. Diabetologia 14: 177–184PubMedCrossRefGoogle Scholar
  40. Srikant CB, McCorkle K, Unger RH (1977) Properties of immunoreactive glucagon fractions of canine stomach and pancreas. J Biol Chem 252: 1847–1851PubMedGoogle Scholar
  41. Stacpoole PW, Jaspan J, Kasselberg AG, Halter SA, Polonsky K, Gluck FW, Liljenquist JE, Rabin D (1981) A familial glucagonoma syndrome. Genetic, clinical and biochemical features. Am J Med 70: 1017–1026PubMedCrossRefGoogle Scholar
  42. Tager HS, Markese J (1979) Intestinal and pancreatic glucagon-like polypeptides. Evidence for identity of higher molecular weight forms. J Biol Chem 254: 2229–2233Google Scholar
  43. Tung AK, Ruse JL, Cockburn E (1980) Glucagon from the bovine fetal pancreas: chromatographic and electrophoretic characterizations of high molecular weight immunoreactive species. Can J Biochem 58: 707–714PubMedCrossRefGoogle Scholar
  44. Unger RH (1976b) Discussion to: Distribution and properties of IRGs in animals and man. Metabolism [Suppl 1] 24: 1412Google Scholar
  45. Valverde I (1977) Quantification of plasma glucagon immunoreactive components in normal and hyperglucagonemic states. In: Foa PP, Bajaj JS, Foa NL (eds) Glucagon: its role in physiology and clinical medicine. Springer, Berlin Heidelberg New York, pp 77– 92Google Scholar
  46. Valverde I, Ghiglione M (1980) Plasma glucagon immunoreactive components. In: Andreani D, Lefebvre PJ, Marks V (eds) Current views on hypoglycemia and glucagon. Academic Press, London New York, pp 21–26Google Scholar
  47. Valverde I, Matesanz R (1977) High levels of plasma “proglucagon” in early life. Diabetes 26: 421Google Scholar
  48. Valverde I, Villanueva ML (1976) Heterogeneity of plasma immunoreactive glucagon. Metabolism [Suppl 1] 24: 1393–1395Google Scholar
  49. Valverde I, Rigopoulou D, Marco J, Faloona G, Unger RH ( 1970 a) Characterization of glucagon-like immunoreactivity ( GLI ). Diabetes 19: 614–623PubMedGoogle Scholar
  50. Valverde I, Rigopoulou D, Marco J, Faloona G, Unger RH ( 1970 b) Molecular size of ex- tractable glucagon and glucagon-like immunoreactivity ( GLI) in plasma. Diabetes 19: 624–629PubMedGoogle Scholar
  51. Valverde I, Villanueva ML, Lozano I, Marco J (1974) Presence of glucagon immunoreactivity in the globulin fraction of human plasma (“big plasma glucagon”). J Clin Endocrinol Metab 39: 1090–1098PubMedCrossRefGoogle Scholar
  52. Valverde I, Dobbs R, Unger RH (1975) Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized and alloxan-diabetic dogs. Metabolism 24: 1021–1028PubMedCrossRefGoogle Scholar
  53. Valverde I, Ghiglione M, Matesanz R, Casado S (1979) Chromatographic pattern of gut glucagon-like immunoreactivity ( GLI) in plasma before and during glucose absorption. Horm Metab Res 11: 343–346PubMedCrossRefGoogle Scholar
  54. Valverde I, Ghiglione M, Calvo G ( 1980 a) Heterogeneity of circulating glucagon and GLI. In: Waldhausl WK (ed) Diabetes 1979. Excerpta Medica, Amsterdam London New York, pp 415–420Google Scholar
  55. Valverde I, Ghiglione M, Pascual JM, Rovira A, Calvo G, Vivanco F ( 1980 b) Glucagon and glucagon-like immunoreactivity in the gastrointestinal tract. In: Cumming IA, Funder JW, Mendelsohn FAO (eds) Endocrinology 1980. Australian Academy of Science, Canberra, pp 554–557Google Scholar
  56. Villanueva ML (1976) PhD thesis. Estudio del glucagon immunorreactivo plasmatico. Caracterizacion del macroglucagon. Complutense University of MadridGoogle Scholar
  57. Villanueva ML, Hedo J A, Marco J (1976) Plasma glucagon immunoreactivity in a totally pancreatectomized patient. Diabetologia 12: 613–616PubMedCrossRefGoogle Scholar
  58. Von Schenck H (1977) Production and characterization of an antiserum against pancreatic glucagon. Clin Chim Acta 80: 455–463CrossRefGoogle Scholar
  59. Von Schenck H (1978) Immunoglobulins interfering in the glucagon radioimmunoassay. Acta Endocrinol (Copenh) [Suppl 219] 88: 69Google Scholar
  60. Von Schenck H, Thorell JI, Berg J, Bojs G, Dymling JF, Hallengren B, Ljungberg O, Tibblin S (1979) Metabolic studies and glucagon gel filtration pattern before and after surgery in a case of glucagonoma syndrome. Acta Med Scand 205: 155–162CrossRefGoogle Scholar
  61. Weir GC (1977) Assesment of glucagon immunoreactivity in plasma. In: Foa PP, Bajaj JS, Foa NL (eds) Glucagon: its role in physiology and clinical medicine. Springer, Berlin Heidelberg New York, pp 65–76CrossRefGoogle Scholar
  62. Weir GC, Turner RC, Martin DB (1973) Glucagon radioimmunoassay using antiserum 30 K: interference by plasma. Horm Metab Res 5: 241–244PubMedCrossRefGoogle Scholar
  63. Weir GC, Knowlton SD, Martin DB (1975) High molecular weight glucagon-like immunoreactivity in plasma. J Clin Endocrinol Metab 40: 296–302PubMedCrossRefGoogle Scholar
  64. Weir GC, Horton ES, Aoki TT, Slovik D, Jaspan J, Rubenstein AH (1977) Secretion by glucagonomas of a possible glucagon precursor. J Clin Invest 59: 325–330PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1983

Authors and Affiliations

  • I. Valverde

There are no affiliations available

Personalised recommendations